You just read:

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer

News provided by

Ability Pharmaceuticals, SL

Dec 13, 2017, 09:30 ET